1. Molodecky, N.A. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. / N.A.Molodecky, I.S.Soon, D.M.Rabi et al. // Gastroenterology. - 2012; 142 (1): 46-54.
2. Munkholm, P. Intestinal cancer risk and mortality in patients with Crohn’s disease. / P.Munkholm, E.Langholz, M.Davidsen et al. // Gastroenterology. -1993; 105 (6): 1716-23.
3. Dignass, A. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. / A.Dignass, G.Assche, J.O.Lindsay et al. // J. Crohns Colitis. -2010; 4: 28-62.
4. Peyrin-Biroulet, L. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. / L.Peyrin-Biroulet, A.Oussalah, N.Williet et al. // Gut. - 2011; 60 (7): 930-36.
5. Sandborn, W.J. Current directions in IBD therapy: what goals are feasible with biological modifiers? / W.J.Sandborn // Gastroenterology. - 2008; 135 (5): 1442-44.